Charles Jillings, CEO of Utilico, energized by strong economic momentum across Latin America. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
I agree with you LW, that we’re shooting in the dark and whether it’s twenty or ten cents is not going to make a tangible difference to many of us. Personally I’m not sure what success can look like pre-clinical with a six months timeline so I’m not bought into the rabbits and hats argument but on the other hand if Mr Ross creates an auction then the acquisition premium no longer applies. Let’s therefore hope that more than one bidder likes it …….. actually let’s hope someone likes it.
I think - if successful of course - it will be much better than 14p, but well short of the pounds per share that some LTH's would have paid.
For those investors, even early/mid 20p territory would probably feel no different to 14p.
That might be too conservative a range of course, but equally, to avoid running the risk of coming across as ramping, it might be too optimistic too.
Presumably not long to find out now, one way or the other. GLA.
Historical purchase premium on acquisitions are in the range of 10-50% over market trading value. Let’s be optimistic and say trading value is ten cents and purchase premium is 40% ie the acquirer would pay 14 pennies. You right LW I certainly wouldn’t wash my face but hopefully others will. C’est la vie.
Not sure we need an exact date. April is close enough!
Assuming the IP and general business is of value, which presumably Iain and the other Directors who bought shares here think there is, then IMO a deal will be struck before that stage. No guarantees a suitor would get the goods if it comes down to administration, to that point.
But is it, or is it not? That is the question!
IMO, Iain will get an outcome that will reward shareholders that have a low average, but I cannot see LTH's breaking even, let alone making a profit. Would be delighted to be wrong about that naturally.
And also prepared to be wrong entirely and take the consequences of that on my holding here.
You pays your money and makes your choice etc. GLA.
Looking at yesterday’s sale data, someone clearly needed five bucks to buy some Bud! But to Steve’s point about April being when we get put out of our misery, does anyone have a more exact date? Clearly the closer to the edge and the higher the desperation, the weaker Mr Ross’s hand. Given there’s only the janitor left has it any value as a going concern? Potential buyers who know and who work with the technology under agreement may think they’ll get a better deal on assets from an appointed administrator. But who knows?
Well, my purchase the other day was smart.
Come on, Iain, give us some good news!
Not that it matters of course, but the 10K showing as a sell, was in fact a buy.
GLA.
Company reporting progress today. In vivo data is one step on from In Vitro data. Means company now in a position to engage better with partners and is the route to cash inflows. Interesting, speculative nano-cap.
Most of these Pharmaceuticals company's extremely high risk, most come too nothing, 4ever raising, highly unlikely rene will come too anything, believe there financed till April next year
Wink, buying penny stocks is much more akin to playing the lotto or spinning the roulette wheel than it is to investing. Whilst on this board, as there is in Vegas there’s fancy strategies posted the house aka the executive in this case, who’ve been paid for the ride, always wins. Nonetheless like rolling the ball or playing the lotto we hope to be lucky, but I’m not quite sure thats investing.
To say I am disalosioned would be a understatement please tell me anybody in the last twenty years have made any money investing in the broken promises by Rene unfortunately this is the worst share out what broker would put his name to this company let me know if you find one!
Actually thought it was tomorrow but presumably nothing of much note came up?
Clivealive,
I think many of us are a bit in the dark as to why the stroke and RP trials were abandoned (on scientific grounds rather than, ahem, any other reason). However, I think an explanation of sorts can be found in a recent lecture given by Professor Jack Price who puts these into context - he was actually involved with the Reneuron stroke research and uses this as an example along with a few others that are equally informative. RP is brought up in the Q&A bit.
Obviously we all hope Leonard is well...but the prof also demonstrates the danger of using single examples flashed over the media giving false hope to sufferers. He gives the example of Duke University selling autism stem cell therapy EVEN AFTER their Phase 2 trial failed. Insane.
If your interested, the lecture is titled, "The Future of Brain Repair: the prospects for stem cell therapy" and was given on 23rd June 2023. It's on YouTube:
https://www.youtube.com/watch?v=6p1zekBu7MY
It's over an hour in length...you could skip the first 20 mins. But overall its pure gold!
DYOR.
Appreciate lack of resources has meant shelving of initial trials for stroke in favour of Exosomes, but we had a phase 2 trial, which was reviewed by the BBC showing the patient Leonard and his improvements from the ReNeuron stem cell injections - ref https://www.reneuron.com/news-list/bbc-breakfast-news-interview-stem-cells-used-in-stroke-treatment/ - This was powerful stuff from the back catalogue and still would merit an update on Lenard's progress and whether he is now touching his nose with his left hand and walking better? Would provide confidence knowing that work by Fosum is still active on this? The BBC indicated they would like to follow up on progress, could be very effective low cost PR which if achieved would greatly assist partner deal and fund raising. Indeed a clever deal with The British Heart Foundation who are a cardiovascular research charity in the United Kingdom, with a donation of future profits percentage would also be a clever move! I hope this is picked up by new management team.
Good find, thanks. I think we can expect an Rns on the day or just before. More than likely will discuss the data they have been talking about. Hopefully they are already in discussions with companies to sign deals.
The CSO will be presenting on the 6th September in Boston, MA, with a talk entitled, "Targeted Delivery of Therapeutic Payloads Using Stem Cell- Derived Exosomes". I'm hoping it will summarise the latest work.
https://exosomebased-therapeutics.com/speakers/
Correct.
For what its worth, here's my view on where exosome tech could take us...
Many diseases are directly linked to cellular aging, aka senescence, aka dysregulation. Medicine has historically treated the symptoms (eg. arthritis, kidney disease, heart disease, etc) of this dysregulation rather than the cause. Think pain relief or chopping out and replacing of a joint, or using blood thinners perhaps. It has been assumed that such an aging process at the cellular level is inevitable and therefore untreatable. This view may need revision if you consider the latest findings using exosomes. An example of this, IMO, is here:
https://www.nature.com/articles/s41598-023-39370-5
Capricor Therapeutics in the US had a hand in this particular research, but I think this should be used as an exemplar for exosome development, given the obvious massive potential. Hell, it could even save the NHS! DYOR.
I have had Rene for over twenty years never in that time have I received 1 divi also they only gone down, full of promises but only broken ones I invested for my children, research I know is a risky business. Why can,t they be like Astra Zeneca!
Steady move up again this week? Catchee monkey strategy....
Would not be worth it for the trading costs. Mine were a couple of the 5K buys.
The SP action the past few days has been very interesting. I am anticipating another red day across the markets.
If this comes to pass, it will be fascinating to see how this one goes.
Might take a few more for myself if we get a savage sell off, but if we see similar price action in this company to yesterday, I think that would be cause for some real optimism.
Anyway, not long to find out. GLA.
Someone bought 95 for ten bucks. Was that the kid’s allowance LW?
It is my money, although technically not, insofar as it is theirs officially and will be their p/f to manage when they are of age.
But losses on their behalf sting more than my own, if you see what I mean :)
Investing your kids money GL, personally only invest money I'm prepared too lose, my own money, particularly these type of stocks,
Bought a few for the kids today.
Only a small allocation, but proof of my faith in Iain to deliver!
It also matters a lot more to me when I decide to buy stocks for them, even though the positions are only a small fraction of my typical purchase sizes...so gulp! GLA.